Doctors Without Borders/Médecins Sans Frontières (MSF) frequently publishes updates, press releases, and other forms of communication about its work in more than 60 countries around the world. See the list below for the most recent updates or search by location, topic, or year.

November 07, 2016

In an attempt to break up the everyday routine for children undergoing tuberculosis treatment in Tajikistan, the MSF psychosocial team organizes celebration parties as part of MSF’s pediatric therapeutic play program.

October 25, 2016

South Africa has one of the highest burdens of tuberculosis (TB) and drug-resistant tuberculosis (DR-TB) in the world, with more than 20,000 people diagnosed with DR-TB in 2015. Yet the current DR-TB treatment regimen—which consists of a combination of multiple pills and daily injections—is only successful in about half of all people who receive it. New drugs such as delamanid offer the opportunity to provide more successful, tolerable treatment regimens to patients with few other options available.

May 12, 2016

The World Health Organization has just recommended that countries move toward shorter treatment regimens for some people with drug-resistant tuberculosis (DR-TB), including people co-infected with HIV, children, and people with simple MDR-TB who have not been treated before or and have no known resistance to any of the drugs in the regimen. This recommendation comes following results from a number of large observation cohort studies using the shortened regimen.

March 23, 2016

Since 2006, Doctors Without Borders/Médecins Sans Frontières (MSF) has been providing ambulatory medical and psychosocial care for people in Mumbai living with drug-resistant tuberculosis (DRTB), HIV, hepatitis C, or a combination of these diseases. The majority of the patients are HIV positive who require second or third line treatment. Narendra* is one of only two percent of drug-resistant TB patients in need that have access to these new drugs.

March 21, 2016

New York/Geneva, March 21, 2016—Two years after two new drugs to treat tuberculosis (TB)—the first in over 50 years—were conditionally approved for use, only two percent of the 150,000 people who need them most have been able to access them, according to Doctors Without Borders’ new edition of DR-TB Drugs Under the Microscope.

February 24, 2016

International medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it would make delamanid available to some developing countries at a price of $1,700 per treatment course.

December 02, 2015

The 2015 Out of Step report presents the results of a survey of 24 countries conducted by Stop TB Partnership and MSF. Building on the first edition of Out of Step published in 2014, this year’s survey tracked of the latest tuberculosis policies, guidelines, and tools across five areas: diagnosis and drug resistance testing; drug-sensitive TB (DS-TB) treatment regimens; MDR-TB treatment regimens; models of care; and regulatory frameworks.

December 02, 2015

GENEVA/CAPE TOWNDoctors Without Borders/Médecins Sans Frontières (MSF) and the Stop TB Partnership today released the second edition of the Out of Step report, a 24-country survey of policies and practices used today to guide the diagnosis and treatment of tuberculosis (TB).

July 08, 2015

Doctors Without Borders/Médecins Sans Frontières (MSF) says a new combination of drugs created to treat extensively drug-resistant tuberculosis (XDR-TB) is having a significant impact on a group of patients in the midst of a two-year treatment to cure their disease.

In 2013, an MSF team in Grozny noticed that a growing number of patients with multidrug-resistant TB (MDR-TB) were not responding to second-line drugs, and there was no alternative medication available in the country to help them.

March 20, 2015

endTB will provide access to new anti-TB drugs for more than 3,000 people and run clinical trials to identify safer and more effective treatments.

Pages